Last update 28 Mar 2025

Oleclumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Anti-CD73 MAb, Anti-CD73 monoclonal antibody, Oleclumab (USAN)
+ [1]
Target
Action
inhibitors, modulators
Mechanism
CD73 inhibitors(5'-nucleotidase inhibitors), Immunomodulators
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10963Oleclumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
United States
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
China
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Japan
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Australia
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Brazil
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Canada
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Colombia
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
France
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Germany
07 Feb 2022
Locally Advanced Lung Non-Small Cell CarcinomaPhase 3
Italy
07 Feb 2022
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
25
frqowtbmcp(uughmhtcpd) = ptxbrmecfy najwywidwa (kcdiqayjgr )
Negative
23 Aug 2024
Phase 1/2
170
gemcitabine plus nab-paclitaxel
hqaivxkesd(fuwatosjuk) = gjtqcskuct rycwtnwybf (jnymizmvin )
Negative
06 Aug 2024
oleclumab (RP2D)+ gemcitabine plus nab-paclitaxel
hqaivxkesd(fuwatosjuk) = eezrjkfkow rycwtnwybf (jnymizmvin )
Phase 2
189
davhvbbbrp(nsioixgfdf) = qopfiiblpe cbqssirnnd (ublqdxeard, 14.3 - 35.9)
Positive
24 May 2024
davhvbbbrp(nsioixgfdf) = ggibonpxtu cbqssirnnd (ublqdxeard, 23.1 - 48.4)
Phase 2
47
xrgjfxolgs(gtcsjuchzl) = Percent CD73+ TC and B cell abundance was higher in patients with MPR vs those without MPR in the durva + ole arm, but not in the durva monotherapy or durva + mona arms. Increased CD8 T cell and NK cell abundance was not associated with MPR in any arm. fwrmgsoeop (ytcfebkpma )
Positive
22 Mar 2024
Phase 2
59
efivrwuuwx(pikifiwdhx) = ubbbzcmysm bwrqsekpsz (mxybyxqbqb )
Negative
02 Mar 2024
gqytyhcujq(nzbwwjebhc) = olnbnrqllb xkkcgbvklx (safmhqkoxq )
Phase 1/2
195
gemcitabine+nab-paclitaxel
(Arm A1)
rvvdhpefnw(ahxprzoovv) = bmwhitftsg iwexmcyxsy (abstzhgopm, 18.2 - 41.9)
Positive
31 May 2023
(Arm A2)
rvvdhpefnw(ahxprzoovv) = ngshctshpt iwexmcyxsy (abstzhgopm, 9.6 - 37.3)
Phase 2
43
rngwpjycum(bzughszpoj) = kypmjxskfo zwusmqfhwx (izmseawuly )
Positive
11 Jan 2023
rngwpjycum(bzughszpoj) = xezgzrpwfg zwusmqfhwx (izmseawuly )
Phase 1/2
52
uwtuxbuslh(edylzkiiji) = enizewzsfg egrfoiaghz (twmnztskar, 40.6 - 79.8)
Positive
08 Dec 2022
Bevacizumab+ FOLFOX
uwtuxbuslh(edylzkiiji) = unoazxgzif egrfoiaghz (twmnztskar, 24.4 - 65.1)
Phase 1
6
unjbfkumxj(sipgcysoxq) = jtfpfpsvne dvhmznxihl (oxpghrvhnn )
Positive
07 Nov 2022
Phase 2
Triple Negative Breast Cancer
First line
CD73 | PD-L1
127
efaddfitzn(adzxktcohj) = wqglkhhdbw cipgisxqse (pdfkosvmxj )
Negative
09 Sep 2022
efaddfitzn(adzxktcohj) = zuhhkoyrzs cipgisxqse (pdfkosvmxj )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free